Early Chimerism Threshold Predicts Sustained Engraftment and NK-cell Tolerance in Prenatal Allogeneic Chimeras

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Sep 18

PMID 18796629

Citations 32

Authors

Emily T Durkin

Kelly A Jones

Deepika Rajesh

Aimen F Shaaban

Affiliations

Soon will be listed here.

Abstract

The failure of engraftment in human cases of in utero hematopoietic cell transplantation (IUHCT) in which no immunodeficiency exists suggests the presence of an unrecognized fetal immune barrier. A similar barrier in murine IUHCT appears to be dependent on the chimerism level and is poorly explained by a lack of T-cell tolerance induction. Therefore, we studied the effect of the chimerism level on engraftment and host natural killer (NK)-cell education in a murine model of IUHCT. The dose of transplanted cells was found to exhibit a strong correlation with both the engraftment rate and chimerism level. More specifically, a threshold level of initial chimerism (> 1.8%) was identified that predicted durable engraftment for allogeneic IUHCT, whereas low initial chimerism (< 1.8%) predicted a loss of engraftment. NK cells taken from chimeras above the "chimerism threshold" displayed durable calibration of alloresponsive Ly49A receptors and tolerance to donor antigens. Depletion of recipient NK cells stabilized engraftment in low-level chimeras (< 1.8%). These studies illustrate the importance of the early chimerism threshold in predicting long-term engraftment and host NK-cell tolerance after in utero transplantation.

Citing Articles

Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation.

Riley J, Berkowitz C, Luks V, Dave A, Cyril-Olutayo M, Pogoriler J Blood Adv. 2024; 8(17):4523-4538.

PMID: 38941538 PMC: 11395771. DOI: 10.1182/bloodadvances.2023012247.

Maternal dendritic cells influence fetal allograft response following murine in-utero hematopoietic stem cell transplantation.

Kandasamy K, Johana N, Tan L, Tan Y, Yeo J, Yusof N Stem Cell Res Ther. 2023; 14(1):136.

PMID: 37226255 PMC: 10206581. DOI: 10.1186/s13287-023-03366-9.

Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Shi C, Pan L, Hu Z Front Pharmacol. 2022; 13:851375.

PMID: 36120324 PMC: 9478511. DOI: 10.3389/fphar.2022.851375.

Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity.

Li K, Wu C, Lu C, Shen C, Kuo Y, Tsai C Int J Mol Sci. 2021; 22(5).

PMID: 33668117 PMC: 7956485. DOI: 10.3390/ijms22052236.

Therapy for the Treatment of Sickle Cell Disease: Taking Advantage of the Fetal Immune System.

Saenz de Villaverde Cortabarria A, Makhoul L, Strouboulis J, Lombardi G, Oteng-Ntim E, Shangaris P Front Cell Dev Biol. 2021; 8:624477.

PMID: 33553164 PMC: 7862553. DOI: 10.3389/fcell.2020.624477.

References

Taylor P, McElmurry R, Lees C, Harrison D, Blazar B . Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipients. Blood. 2002; 99(5):1870-2. DOI: 10.1182/blood.v99.5.1870. View

Carrier E, Gilpin E, Lee T, Busch M, Zanetti M . Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity. J Lab Clin Med. 2000; 136(3):224-35. DOI: 10.1067/mlc.2000.108942. View

Kim H, Shaaban A, Yang E, Liechty K, Flake A . Microchimerism and tolerance after in utero bone marrow transplantation in mice. J Surg Res. 1998; 77(1):1-5. DOI: 10.1006/jsre.1997.5255. View

Archer D, Turner C, Yeager A, Fleming W . Sustained multilineage engraftment of allogeneic hematopoietic stem cells in NOD/SCID mice after in utero transplantation. Blood. 1997; 90(8):3222-9. View

Stewart F, Crittenden R, Lowry P, Pearson-White S, Quesenberry P . Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 1993; 81(10):2566-71. View

Alter G, Malenfant J, Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294(1-2):15-22. DOI: 10.1016/j.jim.2004.08.008. View

Phillips J, Hori T, Nagler A, Bhat N, Spits H, Lanier L . Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J Exp Med. 1992; 175(4):1055-66. PMC: 2119193. DOI: 10.1084/jem.175.4.1055. View

Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, Horwitz E . Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005; 79(11):1607-14. DOI: 10.1097/01.tp.0000159029.48678.93. View

Widmer M, Cooper E . Ontogeny of cell-mediated cytotoxicity: induction of CTL in early postnatal thymocytes. J Immunol. 1979; 122(1):291-5. View

10.

Johansson M, Bieberich C, Jay G, Karre K, Hoglund P . Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med. 1997; 186(3):353-64. PMC: 2199002. DOI: 10.1084/jem.186.3.353. View

11.

Shields L, Gaur L, Gough M, Potter J, Sieverkropp A, Andrews R . In utero hematopoietic stem cell transplantation in nonhuman primates: the role of T cells. Stem Cells. 2003; 21(3):304-14. DOI: 10.1634/stemcells.21-3-304. View

12.

Westerhuis G, Maas W, Willemze R, Toes R, Fibbe W . Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood. 2005; 106(6):2215-20. DOI: 10.1182/blood-2005-04-1391. View

13.

CUDKOWICZ G, Bennett M . Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med. 1971; 134(6):1513-28. PMC: 2139114. DOI: 10.1084/jem.134.6.1513. View

14.

Grzywacz B, Kataria N, Sikora M, Oostendorp R, Dzierzak E, Blazar B . Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006; 108(12):3824-33. PMC: 1895469. DOI: 10.1182/blood-2006-04-020198. View

15.

Sivakumar P, Gunturi A, Salcedo M, Schatzle J, Lai W, Kurepa Z . Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development. J Immunol. 1999; 162(12):6976-80. View

16.

Omoto K, Umesue M, Murakami Y, Matsuzaki G, Nomoto K . Tolerance induction in a fully allogeneic combination using anti-T cell receptor-alpha beta monoclonal antibody, low dose irradiation, and donor bone marrow transfusion. Transplantation. 1995; 59(3):395-401. View

17.

Chung D, Natarajan K, Boyd L, Tormo J, Mariuzza R, Yokoyama W . Mapping the ligand of the NK inhibitory receptor Ly49A on living cells. J Immunol. 2000; 165(12):6922-32. DOI: 10.4049/jimmunol.165.12.6922. View

18.

Dorfman J, Raulet D . Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med. 1998; 187(4):609-18. PMC: 2212149. DOI: 10.1084/jem.187.4.609. View

19.

Ferber I, Schonrich G, Schenkel J, Mellor A, Hammerling G, Arnold B . Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science. 1994; 263(5147):674-6. DOI: 10.1126/science.8303275. View

20.

Royo C, Touraine J, de Bouteiller O . Ontogeny of T lymphocyte differentiation in the human fetus: acquisition of phenotype and functions. Thymus. 1987; 10(1-2):57-73. DOI: 10.1007/978-94-009-3365-1_7. View